Loading, please wait....jpg)
.jpg)
CONTINUING PHARMACY EDUCATION
Incorporating Anti-Amyloid-B (AB) Monoclonal Antibody Therapies into Alzheimer’s Disease Management
Speaker: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Dean and Professor, Pacific University School of Pharmacy, Hillboro, OR
ACPE Universal Program ID# 0122-0000-25-078-H01-P
1 Contact Hours [0.1 CEU]
Release Date: November 3, 2025
Expiration Date: November 3, 2028
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Discuss currently available pharmacologic treatments for Alzheimer’s disease
- Explain the role and place in therapy of FDA-approved anti-amyloid-B monoclonal antibodies in the treatment paradigm for Alzheimer’s disease
- Identify patient characteristics and clinical indicators to appropriately select candidates for anti-amyloid-B monoclonal antibody therapy
- Review the risks, benefits, and administration protocols of FDA-approved anti-amyloid-B monoclonal antibodies to facilitate informed decision
Speaker(s)/Author(s)
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
|
Activity Number
0122-0000-25-078-H01-P
Release Date:
Nov 3, 2025
Credit Expiration Date:
Nov 3, 2028
CE Hours
1.00